Your browser doesn't support javascript.
Melatonin as a Potential Adjuvant Treatment for COVID-19 beyond Sleep Disorders.
Wichniak, Adam; Kania, Aleksander; Sieminski, Mariusz; Cubala, Wieslaw Jerzy.
  • Wichniak A; Third Department of Psychiatry and Sleep Medicine Center, Institute of Psychiatry and Neurology, 02-957 Warszawa, Poland.
  • Kania A; Department of Pulmonology, 2nd Department of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, 31-008 Kraków, Poland.
  • Sieminski M; Department of Emergency Medicine, Faculty of Medicine, Medical University of Gdansk, 80-214 Gdansk, Poland.
  • Cubala WJ; Department of Psychiatry, Faculty of Medicine, Medical University of Gdansk, 80-214 Gdansk, Poland.
Int J Mol Sci ; 22(16)2021 Aug 11.
Article in English | MEDLINE | ID: covidwho-1354985
ABSTRACT
Melatonin is registered to treat circadian rhythm sleep-wake disorders and insomnia in patients aged 55 years and over. The essential role of the circadian sleep rhythm in the deterioration of sleep quality during COVID-19 confinement and the lack of an adverse effect of melatonin on respiratory drive indicate that melatonin has the potential to be a recommended treatment for sleep disturbances related to COVID-19. This review article describes the effects of melatonin additional to its sleep-related effects, which make this drug an attractive therapeutic option for treating patients with COVID-19. The preclinical data suggest that melatonin may inhibit COVID-19 progression. It may lower the risk of the entrance of the SARS-CoV-2 virus into cells, reduce uncontrolled hyper-inflammation and the activation of immune cells, limit the damage of tissues and multiorgan failure due to the action of free radicals, and reduce ventilator-induced lung injury and the risk of disability resulting from fibrotic changes within the lungs. Melatonin may also increase the efficacy of COVID-19 vaccination. The high safety profile of melatonin and its potential anti-SARS-CoV-2 effects make this molecule a preferable drug for treating sleep disturbances in COVID-19 patients. However, randomized clinical trials are needed to verify the clinical usefulness of melatonin in the treatment of COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Drug Treatment / Melatonin Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Year: 2021 Document Type: Article Affiliation country: Ijms22168623

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Drug Treatment / Melatonin Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Year: 2021 Document Type: Article Affiliation country: Ijms22168623